NCT02452268 is a Phase 1 clinical trial of NIZ985 in Metastatic and Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT02452268?

NCT02452268 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT02452268?

Interventions in NCT02452268: NIZ985, PDR001.

What condition does NCT02452268 study?

NCT02452268 studies Metastatic and Advanced Solid Tumors.

Is NCT02452268 still recruiting?

NCT02452268 is currently terminated. Last updated 3 March 2023.

Last reviewed 2023-03-03 · How we verify

NCT02452268

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

Terminated Phase 1 Last updated 3 March 2023

What this trial tests

Phase 1 trial testing NIZ985 in Metastatic and Advanced Solid Tumors in 83 participants. Terminated before completion.

Timeline

8 May 2017

Primary endpoint
7 March 2022

7 March 2022

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	83
Start date	8 May 2017
Primary completion	7 March 2022
Estimated completion	7 March 2022
Sites	7 locations across United States

Drugs / interventions tested

NIZ985 — full drug profile →
PDR001 — full drug profile →

Conditions studied

Metastatic and Advanced Solid Tumors — all drugs for Metastatic and Advanced Solid Tumors →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Metastatic and Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the NK cell platform for cancer immunotherapy.
Myers JA, Miller JS. · · 2021 · cited 977× · PMID 32934330 · DOI 10.1038/s41571-020-0426-7
Cytokines in the Treatment of Cancer.
Conlon KC, Miljkovic MD, Waldmann TA. · · 2019 · cited 360× · PMID 29889594 · DOI 10.1089/jir.2018.0019
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, et al · · 2018 · cited 352× · PMID 29628312 · DOI 10.1016/s1470-2045(18)30148-7
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.
Maskalenko NA, Zhigarev D, Campbell KS. · · 2022 · cited 174× · PMID 35314852 · DOI 10.1038/s41573-022-00413-7
The potential and promise of IL-15 in immuno-oncogenic therapies.
Robinson TO, Schluns KS. · · 2017 · cited 155× · PMID 28823521 · DOI 10.1016/j.imlet.2017.08.010
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy.
Yang Y, Lundqvist A. · · 2020 · cited 149× · PMID 33266177 · DOI 10.3390/cancers12123586
Engineering cytokine therapeutics.
Deckers J, Anbergen T, Hokke AM, de Dreu A, et al · · 2023 · cited 132× · PMID 37064653 · DOI 10.1038/s44222-023-00030-y
Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.
Guo Y, Luan L, Patil NK, Sherwood ER. · · 2017 · cited 131× · PMID 28888485 · DOI 10.1016/j.cytogfr.2017.08.002

Verify or expand the search:

Other trials of NIZ985

Trials testing the same drug.

NCT04261439 — A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab · Phase 1 · terminated

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02452268 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 3 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02452268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing